STOCK TITAN
  1. Home
  2. Sec-filings
  3. OTLK
  4. [Form 4] Outlook Therapeutics, Inc. Insider Trading Activity

Outlook Therapeutics (OTLK) CEO granted 100,000 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Outlook Therapeutics, Inc. reports that Chief Executive Officer Robert Charles Jahr received a grant of stock options covering 100,000 shares of common stock at an exercise price of $1.4304 per share. Granted on July 21, 2026 under the 2024 Equity Incentive Plan, the options vest in full on July 21, 2027 and expire on July 21, 2036, leaving him with 100,000 options held directly.

Positive

  • None.

Negative

  • None.
Insider Jahr Robert Charles
Role Chief Executive Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) F1 100,000 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 100,000 shares (Direct)
Footnotes (1)
  1. F1. The option was granted to Mr. Jahr on July 21, 2026, pursuant to the Issuer's 2024 Equity Incentive Plan and the Issuer's standard form of stock option agreement thereunder. The option vests and becomes exercisable in full on July 21, 2027, subject to Mr. Jahr's continuing service with the Issuer through such vesting date.
Option grant size 100,000 shares Stock options to purchase common stock granted to CEO on July 21, 2026
Exercise price $1.4304 per share Conversion or exercise price of the granted stock options
Vesting date July 21, 2027 Date on which the options vest and become fully exercisable
Expiration date July 21, 2036 Date on which the stock options expire
Options held after grant 100,000 options Total stock options held directly by the CEO following the reported grant
Stock Option (Right to Buy) financial
"Security title is Stock Option (Right to Buy) for common stock"
2024 Equity Incentive Plan financial
"granted to Mr. Jahr on July 21, 2026, pursuant to the Issuer's 2024 Equity Incentive Plan"
vests and becomes exercisable financial
"The option vests and becomes exercisable in full on July 21, 2027"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What transaction did Outlook Therapeutics (OTLK) report for its CEO?
Outlook Therapeutics reported that CEO Robert Charles Jahr received a grant of stock options covering 100,000 shares of common stock. The options were granted on July 21, 2026 as part of his equity compensation package under the company’s 2024 Equity Incentive Plan.

What is the exercise price of the Outlook Therapeutics (OTLK) CEO stock options?
The granted stock options have an exercise price of $1.4304 per share for Outlook Therapeutics common stock. This is the price at which CEO Robert Charles Jahr may purchase each share once the options vest and become exercisable.

When do the Outlook Therapeutics (OTLK) CEO options vest and expire?
The options granted to CEO Robert Charles Jahr vest and become fully exercisable on July 21, 2027. They carry a long-term horizon, with an expiration date of July 21, 2036, provided his service with the company continues through the vesting date.

Under which plan were the Outlook Therapeutics (OTLK) CEO options granted?
The options were granted under Outlook Therapeutics’ 2024 Equity Incentive Plan using the issuer’s standard form of stock option agreement. This plan governs the terms of equity awards made to executives and other eligible participants at the company.

How many options does the Outlook Therapeutics (OTLK) CEO hold after this grant?
Following this reported grant, CEO Robert Charles Jahr holds 100,000 stock options directly. These options are currently unvested, will become exercisable in full on July 21, 2027, and are exercisable for an equal number of Outlook Therapeutics common shares.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Jahr Robert Charles
(Last)(First)(Middle)
C/O OUTLOOK THERAPEUTICS, INC.
111 S. WOOD AVE, UNIT #100
(Street)
ISELIN NEW JERSEY 08830
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Outlook Therapeutics, Inc. [ OTLK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/21/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$1.430407/21/2026A100,00007/21/2027(1)07/21/2036Common Stock100,000$0100,000D
Explanation of Responses:
1. The option was granted to Mr. Jahr on July 21, 2026, pursuant to the Issuer's 2024 Equity Incentive Plan and the Issuer's standard form of stock option agreement thereunder. The option vests and becomes exercisable in full on July 21, 2027, subject to Mr. Jahr's continuing service with the Issuer through such vesting date.
Lawrence Kenyon, Attorney-in-Fact07/23/2021
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR